RxSpan MD scores a 86 on our Value Score. These are the top-ranked GLP-1 deals we'd point you to instead — every one scored on the same six factors, with the teaser-rate traps flagged so you pay the honest lower price.
!Pricing to watch. NuDay Rx is a GLP-1 weight-loss telehealth service (on the CareValidate/careGLP platform) that pairs medication with video coaching and lifestyle support.
!Pricing to watch. Real published static pricing across three GLP-1 routes — injectable, oral tablet, and brand-name Ozempic®/Zepbound® — with per-week rates that drop the longer you commit.
!Pricing to watch. CLYR Health is a Florida-based telehealth pharmacy offering compounded GLP-1 weight-loss injections alongside sexual-health, longevity and wellness treatments.
$289/mo cash month-to-month · $169/mo on a 12-month prepay
Save ~93%
!Pricing to watch. The widest medication bench in this ranking — compounded, brand-name and oral — priced off a membership whose $99 headline only holds if you commit for months.
!Pricing to watch. Wisp (hellowisp.com) is a US telehealth provider whose weight care vertical offers brand-name Wegovy, Zepbound, and Saxenda alongside a compounded sublingual semaglutide drops formulation at $225/month.
!Pricing to watch. Good headline prices and four routes to a GLP-1 — but every cheapest number it advertises is a year-long commitment, and the month-to-month price is the one to judge it on.
$190/mo month-to-month ($99 first month, renews at $165)
Save ~86%
!Pricing to watch. A LegitScript-certified, physician-supervised program that's one of the few offering a genuine oral GLP-1 tablet alongside injectable — with transparent flat monthly pricing and no insurance required.
Ranked by our Value Score — our editorial judgment per the methodology. “Save” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Assume any provider we list may compensate us — it never changes a Value Score. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.